目的了解信阳市丙型肝炎病毒(hepatitis C virus,HCV)基因型分布特征,为丙型肝炎(丙肝)临床治疗方案的选择提供依据。方法收集2015—2023年南阳市丙肝临床诊断和确诊病例,筛选丙肝病毒载量(HCV-RNA)≥1.0×10~3IU/mL病例的血清样本...目的了解信阳市丙型肝炎病毒(hepatitis C virus,HCV)基因型分布特征,为丙型肝炎(丙肝)临床治疗方案的选择提供依据。方法收集2015—2023年南阳市丙肝临床诊断和确诊病例,筛选丙肝病毒载量(HCV-RNA)≥1.0×10~3IU/mL病例的血清样本,进行HCV基因型检测,描述性分析基因型人群分布、时间分布及地区分布特征。结果795例丙肝病例血清样本中,共检出1、2、3、6等4种HCV基因型,1b、2a、3a、3b、6a等5种基因亚型。主要为1b型646例(81.26%),其次为2a型138例(17.36%)。不同性别HCV基因型分布差异无统计学意义(χ^(2)=1.675,P>0.05)。1型基因15~<31岁构成比最高(100.00%),41~<51岁年龄组最低(77.46%);2型基因在41~<51岁年龄组构成比最高(19.72%),15~<31岁年龄组最低(0.00%)。2015—2019年检出1b型和2a型2种亚型,2020、2022、2023年分别新增3a型、6a型、3b型和混合型。11个县区丙肝患者基因型均以1b型为主,构成比为58.00%~95.65%。结论2015—2023年信阳市丙肝基因型主要以1b型和2a型为主,2020—2023年逐渐增加至4种基因型、5种基因亚型。在丙肝治疗前推荐进行HCV分型检测,以便临床选择基因型特异性方案,对减轻疾病负担有重要意义。展开更多
AIM:To analyze the correlation between CD14 rs2569190/C-159T single nucleotide polymorphism (SNP) and disease progression in chronic hepatitis C.METHODS: Liver biopsy specimens from a total of 137 and 349 patients wit...AIM:To analyze the correlation between CD14 rs2569190/C-159T single nucleotide polymorphism (SNP) and disease progression in chronic hepatitis C.METHODS: Liver biopsy specimens from a total of 137 and 349 patients with chronic hepatitis C were separately evaluated with respect to necroinflammatory activity (grading) and architectural changes (staging). In one group, further histological lesions characteristic for hepatitis C, hepatitis C virus subtypes, and biochemical parameters of liver disease were also investigated. Samples of genomic DNA were genotyped for the respective SNP by 5'-nuclease assays using fluorescent dye-labeled allele-specif ic probes.RESULTS: Genotype distribution did not deviate from the Hardy-Weinberg equilibrium. In the first group, patients homozygous for the variant allele T were found to be younger than C allele carriers (39.6±12.5 vs 45.7±11.5, P=0.008). Among the histological lesions studied, portal lymphoid aggregates were more frequently observed among TT homozygotes than among C carriers (21/37 vs 32/100, P=0.008). The presence of portal lymphoid aggregates was closely correlated with hepatic inflammation (P=0.003) and with bile duct damage (P<0.001). The degree of fibrosis, in contrast, was not found to be related to the CD14 gene C-159T polymorphism.CONCLUSION: The data suggest a possible relationship between CD14 C-159T polymorphism and the formation of portal lymphoid aggregates, but not liver fibrosis progression in chronic hepatitis C.展开更多
Prophylactic DNA vaccines against the influenza virus are promising alternatives to conventional vaccines. In this study, we generated two candidate gene-based influenza vaccines encoding either the seasonal or pandem...Prophylactic DNA vaccines against the influenza virus are promising alternatives to conventional vaccines. In this study, we generated two candidate gene-based influenza vaccines encoding either the seasonal or pandemic hemagglutinin antigen （HA） from the strains A/New Caledonia/20/99 （HIN1） （pV1AS） and A/Califorrtia/04/2009 （H1N1） （pVEH1）, respectively. After verifying antigen expression, the immunogenicity of the vaccines delivered intramuscularly with electroporation was tested in a mouse model. Sera of immunized animals were tested in hemagglutination inhibition assays and by ELISA for the presence of HA-specific antibodies. HA-specific T-cells were also measured in IFN-γ ELISpot assays. The protective efficacy of the candidate influenza vaccines was evaluated by measuring mortality rates and body weight after a challenge with 100 LD50 of mouse-adapted A/New Caledonia/20/99 （H1N1）. Mice immunized with either one of the two vaccines showed significantly higher T cell and humoral immune responses （P〈0.05） than the pVAX1 control group. Additionally, the pV1A5 vaccine effec- tively protected the mice against a lethal homologous mouse-adapted virus challenge with a survival rate of 100% compared with a 40% survival rate in the pVEH1 vaccinated group （P〈0.05）. Our study indicates that the seasonal influenza DNA vac- cine completely protects against the homologous A/New Caledonia/20/99 virus （H1N1）, while the pandemic influenza DNA vaccine only partially protects against this virus.展开更多
文摘目的了解信阳市丙型肝炎病毒(hepatitis C virus,HCV)基因型分布特征,为丙型肝炎(丙肝)临床治疗方案的选择提供依据。方法收集2015—2023年南阳市丙肝临床诊断和确诊病例,筛选丙肝病毒载量(HCV-RNA)≥1.0×10~3IU/mL病例的血清样本,进行HCV基因型检测,描述性分析基因型人群分布、时间分布及地区分布特征。结果795例丙肝病例血清样本中,共检出1、2、3、6等4种HCV基因型,1b、2a、3a、3b、6a等5种基因亚型。主要为1b型646例(81.26%),其次为2a型138例(17.36%)。不同性别HCV基因型分布差异无统计学意义(χ^(2)=1.675,P>0.05)。1型基因15~<31岁构成比最高(100.00%),41~<51岁年龄组最低(77.46%);2型基因在41~<51岁年龄组构成比最高(19.72%),15~<31岁年龄组最低(0.00%)。2015—2019年检出1b型和2a型2种亚型,2020、2022、2023年分别新增3a型、6a型、3b型和混合型。11个县区丙肝患者基因型均以1b型为主,构成比为58.00%~95.65%。结论2015—2023年信阳市丙肝基因型主要以1b型和2a型为主,2020—2023年逐渐增加至4种基因型、5种基因亚型。在丙肝治疗前推荐进行HCV分型检测,以便临床选择基因型特异性方案,对减轻疾病负担有重要意义。
基金Supported by A grant of the Deutsche Forschungsgemeinschaft MI 474/1-1Askar E was supported by a scholarship from Damascus University,Syria
文摘AIM:To analyze the correlation between CD14 rs2569190/C-159T single nucleotide polymorphism (SNP) and disease progression in chronic hepatitis C.METHODS: Liver biopsy specimens from a total of 137 and 349 patients with chronic hepatitis C were separately evaluated with respect to necroinflammatory activity (grading) and architectural changes (staging). In one group, further histological lesions characteristic for hepatitis C, hepatitis C virus subtypes, and biochemical parameters of liver disease were also investigated. Samples of genomic DNA were genotyped for the respective SNP by 5'-nuclease assays using fluorescent dye-labeled allele-specif ic probes.RESULTS: Genotype distribution did not deviate from the Hardy-Weinberg equilibrium. In the first group, patients homozygous for the variant allele T were found to be younger than C allele carriers (39.6±12.5 vs 45.7±11.5, P=0.008). Among the histological lesions studied, portal lymphoid aggregates were more frequently observed among TT homozygotes than among C carriers (21/37 vs 32/100, P=0.008). The presence of portal lymphoid aggregates was closely correlated with hepatic inflammation (P=0.003) and with bile duct damage (P<0.001). The degree of fibrosis, in contrast, was not found to be related to the CD14 gene C-159T polymorphism.CONCLUSION: The data suggest a possible relationship between CD14 C-159T polymorphism and the formation of portal lymphoid aggregates, but not liver fibrosis progression in chronic hepatitis C.
基金supported by the National High Technology Research and Development Program of China(Grant No.2006AA10A205)the National Key Technology Research and Development Program(Grant No. 2006BAD06A05)the National Key Program for Infectious Diseases of China(Grant No.2009ZX10004-103)
文摘Prophylactic DNA vaccines against the influenza virus are promising alternatives to conventional vaccines. In this study, we generated two candidate gene-based influenza vaccines encoding either the seasonal or pandemic hemagglutinin antigen （HA） from the strains A/New Caledonia/20/99 （HIN1） （pV1AS） and A/Califorrtia/04/2009 （H1N1） （pVEH1）, respectively. After verifying antigen expression, the immunogenicity of the vaccines delivered intramuscularly with electroporation was tested in a mouse model. Sera of immunized animals were tested in hemagglutination inhibition assays and by ELISA for the presence of HA-specific antibodies. HA-specific T-cells were also measured in IFN-γ ELISpot assays. The protective efficacy of the candidate influenza vaccines was evaluated by measuring mortality rates and body weight after a challenge with 100 LD50 of mouse-adapted A/New Caledonia/20/99 （H1N1）. Mice immunized with either one of the two vaccines showed significantly higher T cell and humoral immune responses （P〈0.05） than the pVAX1 control group. Additionally, the pV1A5 vaccine effec- tively protected the mice against a lethal homologous mouse-adapted virus challenge with a survival rate of 100% compared with a 40% survival rate in the pVEH1 vaccinated group （P〈0.05）. Our study indicates that the seasonal influenza DNA vac- cine completely protects against the homologous A/New Caledonia/20/99 virus （H1N1）, while the pandemic influenza DNA vaccine only partially protects against this virus.
